Health and Human Services News and Research RSS Feed - Health and Human Services News and Research

FDA approves Medtronic's ‘artificial pancreas’ for type 1 diabetes patients

FDA approves Medtronic's ‘artificial pancreas’ for type 1 diabetes patients

The U.S. Food and Drug Administration today approved Medtronic's MiniMed 670G hybrid closed looped system, the first FDA-approved device that is intended to automatically monitor glucose (sugar) and provide appropriate basal insulin doses in people 14 years of age and older with type 1 diabetes. [More]
Intermediate risk prostate cancer patients can achieve survival benefit with brachytherapy alone

Intermediate risk prostate cancer patients can achieve survival benefit with brachytherapy alone

For men with intermediate risk prostate cancer, radiation treatment with brachytherapy alone can result in similar cancer control with fewer long-term side effects, when compared to more aggressive treatment that combines brachytherapy with external beam therapy (EBT), according to research presented today at the 58th Annual Meeting the American Society for Radiation Oncology. [More]
Increasing adoption of SBRT improves survival rates for older patients with early stage lung cancer

Increasing adoption of SBRT improves survival rates for older patients with early stage lung cancer

Survival rates for elderly patients who received stereotactic body radiation therapy (SBRT) for early stage non-small cell lung cancer (NSCLC) rose from roughly 40 to 60 percent over the past decade, concurrent with the increasing adoption of SBRT, according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology. [More]
IMRT reduces risk of side effects, improves quality of life for endometrial and cervical cancer patients

IMRT reduces risk of side effects, improves quality of life for endometrial and cervical cancer patients

Patients with cervical and endometrial cancer have fewer gastrointestinal and genitourinary side effects and experience better quality of life when treated with intensity-modulated radiation therapy (IMRT) than with conventional radiation therapy (RT), according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology. [More]
Study reveals radiosurgery as viable treatment option for patients with resected brain metastases

Study reveals radiosurgery as viable treatment option for patients with resected brain metastases

For patients who have cancer that has metastasized to the brain, stereotactic radiosurgery (SRS) results in statistically comparable survival rates, reduced cognitive decline and better quality of life (QOL), compared to whole brain radiotherapy (WBRT), according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology. [More]
Hypofractionated RT can reduce treatment time by half in stage II and III NSCLC patients

Hypofractionated RT can reduce treatment time by half in stage II and III NSCLC patients

For patients with stage II and III non-small cell lung cancer (NSCLC) unable to receive standard treatments of surgery or chemoradiation (CRT), hypofractionated radiation therapy (RT) results in similar overall survival (OS) and progression-free survival (PFS) rates, limited severe side effects and shorter treatment times when compared to conventional RT, according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology. [More]
SRS reduces likelihood of local recurrence of brain metastases in cancer patients

SRS reduces likelihood of local recurrence of brain metastases in cancer patients

Stereotactic radiosurgery (SRS) for cancer patients who receive the treatment for brain metastases decreases the likelihood of local recurrence but shows no positive difference in terms of overall survival (OS) or distant brain metastases (DBMs) rates, when compared to observation alone following surgical resection of brain metastases, according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology. [More]
Researchers identify, validate three distinct molecular subtypes of prostate cancer

Researchers identify, validate three distinct molecular subtypes of prostate cancer

In the largest study of its kind to date, researchers have identified and validated three distinct molecular subtypes of prostate cancer that correlate with distant metastasis-free survival and can assist in future research to determine how patients will respond to treatment, according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology. [More]
Increased use of SBRT linked to improved survival outcomes of NSCLC patients

Increased use of SBRT linked to improved survival outcomes of NSCLC patients

A new analysis of records in the Veteran's Affairs Central Cancer Registry demonstrates a clear positive impact of the increased use of stereotactic body radiation therapy (SBRT) to treat patients with stage I non-small cell lung cancer (NSCLC) in recent years, according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology. [More]
FDA approves new biosimilar for multiple inflammatory diseases

FDA approves new biosimilar for multiple inflammatory diseases

The U.S. Food and Drug Administration today approved Amjevita (adalimumab-atto) as a biosimilar to Humira (adalimumab) for multiple inflammatory diseases. [More]
UofL researchers receive NIH funding to explore how environmental exposures influence health of children

UofL researchers receive NIH funding to explore how environmental exposures influence health of children

The National Institutes of Health today announced a team of researchers headed by Janice Sullivan, M.D., of the University of Louisville is among grant recipients nationwide receiving funding for a seven-year, multicenter initiative called Environmental influences on Child Health Outcomes. [More]
Sanford wins $11.7 million NIH grant to translate laboratory cancer research into clinical trials

Sanford wins $11.7 million NIH grant to translate laboratory cancer research into clinical trials

The Cancer Biology Research Center at Sanford Research is the recipient of a five-year, nearly $11.7 million grant from the National Institutes of Health to translate laboratory research into clinical trials for head and neck and pediatric cancers. [More]
Sarepta Therapeutics wins accelerated approval from FDA for Duchenne muscular dystrophy drug

Sarepta Therapeutics wins accelerated approval from FDA for Duchenne muscular dystrophy drug

The U.S. Food and Drug Administration today approved Exondys 51 (eteplirsen) injection, the first drug approved to treat patients with Duchenne muscular dystrophy (DMD). [More]
FDA authorizes marketing of new Aera system to treat patients with chronic ETD symptoms

FDA authorizes marketing of new Aera system to treat patients with chronic ETD symptoms

The U.S. Food and Drug Administration today permitted marketing of a device that uses a small balloon to treat persistent Eustachian tube dysfunction (ETD), a condition in which pressure, pain or clogged or muffled sensations occur in the ear. [More]
FDA warns retailers for selling newly regulated tobacco products to minors

FDA warns retailers for selling newly regulated tobacco products to minors

The U.S. Food and Drug Administration announced today it has taken action against 55 tobacco retailers by issuing the first warning letters for selling newly regulated tobacco products, such as e-cigarettes, e-liquids and cigars, to minors. [More]
Incorporating laughter into exercise program could provide health benefits to older adults

Incorporating laughter into exercise program could provide health benefits to older adults

Incorporating laughter into a physical activity program that is focused on strength, balance and flexibility could improve older adults' mental health, aerobic endurance and confidence in their ability to exercise, according to a study led by Georgia State University. [More]
FDA approval of VisuMax Femtosecond Laser expands surgical treatment options for myopia

FDA approval of VisuMax Femtosecond Laser expands surgical treatment options for myopia

The U.S. Food and Drug Administration today approved the VisuMax Femtosecond Laser for the small incision lenticule extraction (SMILE) procedure to reduce or eliminate nearsightedness in certain patients 22 years of age or older. [More]

FDA awards $21.8 million to support states in implementing FSMA produce safety rule

The U.S. Food and Drug Administration today announced the awarding of a total of $21.8 million to support 42 states to help implement the FDA Food Safety Modernization Act (FSMA) produce safety rule. [More]
TB lesions may remain in lungs long after completion of treatment

TB lesions may remain in lungs long after completion of treatment

Patients with active tuberculosis of the lungs, the infectious form of the disease known as pulmonary tuberculosis (TB), are typically treated with several medications for a period of six months. [More]
Six NIH-funded projects aim to identify biological factors that affect neural regeneration

Six NIH-funded projects aim to identify biological factors that affect neural regeneration

The National Institutes of Health will fund six projects to identify biological factors that affect neural regeneration in the retina. [More]
Advertisement